ArticleInfection and drug resistance2026
Diagnostic Value of Copeptin and Growth Differentiation Factor-15 for Sepsis-Related Myocardial Injury.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biomarkers play a critical role in the diagnosis and clinical decision-making for sepsis-related myocardial injury (SMI). SMI has no single accepted definition. Copeptin and growth differentiation factor-15 (GDF-15), which are associated with stress response and systemic inflammation, have emerged as potential diagnostic markers. This study aimed to investigate the expression levels of copeptin and GDF-15 in SMI patients and evaluate their diagnostic utility. Methods: This case-control study enrolled 148 sepsis patients admitted to the emergency department and 43 healthy controls. Patients with sepsis were divided into the SMI group and the non-SMI group. SMI was defined as cTnT >40.0 pg/mL and/or LVEF <50% in patients with sepsis, after excluding clear alternative causes of myocardial injury. Blood samples were collected within 48 hours after admission, and serum copeptin and GDF-15 levels were measured and compared with clinical indicators. Univariate and multivariate logistic regression analyses were performed to identify factors associated with SMI. The diagnostic performance of copeptin and GDF-15 was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Copeptin and GDF-15 levels were significantly elevated in SMI patients compared to both sepsis patients without myocardial injury and healthy controls ( Conclusion: Serum copeptin and GDF-15 levels were elevated in patients with SMI and may provide complementary value for identifying myocardial injury in patients with sepsis, with enhanced diagnostic capability when used in combination. Further validation in larger multicenter studies is needed before these biomarkers can be used in routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.